Immune checkpoint blockade targeting PD-1 and its ligand PD-L1 has shown promise in the treatment of R/M HNSCC, leading to the approval of pembrolizumab and nivolumab based on the results of KEYNOTE-040 and CheckMate 141 (4, 5). Here, PDCD1 is linked to head and neck squamous cell carcinoma.